Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Crocker Ventures
Deal Size : $6.0 million
Deal Type : Series A Financing
Rebel Medicine Secures Series A and Opens IND for Non-Opioid Pain Therapy
Details : The proceeds will fund a Phase 2 clinical trial in bunionectomy patients to assess the safety and efficacy of Alevatrix, a novel, long‑acting formulation of bupivacaine for postoperative pain.
Product Name : Alevatrix
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 12, 2025
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Crocker Ventures
Deal Size : $6.0 million
Deal Type : Series A Financing